Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 17/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA5A | P35218 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12998221 | 1.00 | STS (0.58) | STSCA2CA12CA1CYP19A1 | |
| SCHEMBL12998231 | 1.00 | STS (0.58) | STSCA2CA12CA1CYP19A1 | |
| SCHEMBL12998216 | 0.99 | STS (0.57) | STSCA2CA12CA1CYP19A1 | |
| SCHEMBL12998214 | 0.96 | STS (0.57) | STSCA2CA12CA1CYP19A1 | |
| SCHEMBL12998219 | 0.82 | STS (0.48) | STSCA2CA12CA1CYP19A1 | |
| SCHEMBL12998223 | 0.82 | STS (0.53) | STSCA2CA12CA1CYP19A1 | |
| SCHEMBL6648775 | 0.76 | PARP1 (0.58) | PARP1 | |
| SCHEMBL12998220 | 0.76 | STS (0.40) | STSCA2CA12CA1CYP19A1 | |
| SCHEMBL12998218 | 0.75 | PARP1 (0.50) | STSCA2CA1CA9PARP1 | |
| SCHEMBL12998207 | 0.75 | STS (0.45) | STSCA2CA12CA1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846965-B2 | a non-steroidal sulphamate compound such as 6-Oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulphamate, suitable for use as an inhibitor of estrone sulphatase, for the treatment of endocrine-dependent cancers and tumors, such as the breast and endometrium | STERIX LIMITED (GB) | 2010-12-07 | — | — | US | disclosed |
| US-20070173531-A1 | Compound | REED MICHAEL J | 2007-07-26 | — | — | US | disclosed |
| US-20070173531-A1 | Compound | REED MICHAEL J | 2007-07-26 | — | — | US | disclosed |
| US-7202272-B2 | Compound | STERIX, LTD. (GB) | 2007-04-10 | — | — | US | disclosed |
| US-7202272-B2 | Compound | STERIX, LTD. (GB) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173531-A1 | Compound | HSD17B11, NR5A1, CYP17A1 | STS 9/4885CA2 796/4885CA12 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.